Stockreport

Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data [Yahoo! Finance]

Definium Therapeutics, Inc. - Common Shares  (DFTX) 
PDF The MDD EMERGE study is a 1:1 randomized, double-blind, placebo-controlled 12-week trial with a 6-week primary MADRS endpoint and is ~80% powered to detect a 5-point pl [Read more]